PubMed Health⌕ Search

Biomedical subjects

T Domzał

Publications and source records attributed to T Domzał.

42 records · Page 3Linked to original sources
PubMedDate not supplied

[Plasmapheresis in neurology -- personal experience].

Since the time of its first therapeutic application in 1956 plasmapheresis has been accepted in neurology in the treatment of life-threatening conditions in autoimmune diseases. The own experience has based on 30 cases treated by this method: 15 cases of Guillain-Barré syndrome, 9 of myasthenia, 3 cases of polyneuropathies of unknown origin, 1 case of dermatomyositis, 1--Fischer syndrome, 1--multiple sclerosis. Twelve patients were in very serious condition with rapidly progressing deterioration. Plasmapheresis was carried out in the acute stage of the disease, possibly early. During one procedure 100-150% of plasma volume was exchanged. The therapeutic course comprised 4-5 procedures. The result was very good in 10 cases, and good in 16. In 3 cases no effect was obtained (Guillain-Barré syndrome and polyneuropathy) and one patient died (carcinomatous polyneuropathy). Plasmapheresis is the method of choice in serious neurological states in Guillain-Barré syndrome and myasthenia.

Adolescent↗
PubMedDate not supplied

[Own experience with botulinum treatment of dystonia].

Fifty-five patients were treated with botulin injections into the muscles showing dystonia, contracture or tremor. Twenty two of them had torticollis, 21 had blepharospasm, 10 had hemifacial spasm, and 2 had tremor. In all, 112 injections were done with good result in 64%, slight effect in 27% and without effect in 9% of the cases. Similar results have been reported from other centers in the world. Adverse effects were not significant and disappeared after several days or weeks. They included ptosis, speech and deglutition disturbances, general weakness and neurotic reactions. These adverse effects developed in 12 cases. In cases of tremor the dose as well as the technique of injections must be individualized. The method is an important therapeutic advance and can be applied in outpatient clinics.

Adult↗
PubMedDate not supplied

-The evaluation of the effectiveness and tolerance of sumatriptan in abortive treatment of migraine attacks (open multicenter trial).

The authors review data on sumatriptan obtained in the results of their own studies performed on 78 patients in 10 Polish neurological centres. In all 154 migraine attacks were treated with 6 mg of subcutaneous sumatriptan. Significant decrease of pain intensity was achieved in 30% of cases after 15 min and 60%--after 30 min. According to the patient's own opinion, 62% of them evaluated the drug as very efficient, 23% of patients--as efficient. Adverse effects were reported by 11 patients (15%), but they were mild and transient. Headache recurred in 16% of patients.

Adult↗
PubMedDate not supplied

[The concept of encephalopathies -- paper for discussion].

The term "encephalopathy" has not yet been strictly defined. In textbooks about 20 adjectives can be found in connection with this term. All encephalopathies have certain features in common: 1. the cause of brain damage is known, 2. the neurological syndrome is diffuse or disseminated, 3. there is the syndrome of organic brain damage (most frequently with dementia). Encephalopathies can be divided into congenital and acquired. Congenital ones are: encephalopathy following perinatal injury or fetal infection. Acquired: post-traumatic, toxic, vascular (hypertensive and atherosclerotic), metabolic, postinflammatory. On the basis of analysis of clinical findings and causes the conclusion may be reached that encephalopathy is a sequela of diffuse organic brain damage, that is, it is a "status post...", but this excludes certain encephalopathies recognize as yet (hypertensive encephalopathy). In medical expertise more precise diagnosis should be required, especially for post-traumatic encephalopathy.

Brain Diseases↗
PubMedDate not supplied

[Piracetam treatment in ischemic stroke].

The increase of interest in piracetam in the treatment of stroke has been noticed lately. The reason of that is the unique double-action of this drug which depends on: 1. its effect on vascular system, and 2. improving of the metabolic process in a nerve cell. The purpose of our work was the evaluation of the therapeutic action of piracetam in comparison with other drugs, which are applied in treating stroke. 171 patients were examined, and piracetam was given to 40 of them. The effects of the treatment were evaluated after 14 days of using piracetam in dose of 12.0 g i.v. The authors estimate, that this drug is efficient in ischaemic stroke. However, its definite superiority over other drugs has not been firmly stated.

Aged↗